Edge Therapeutics, Inc     Print Page | Close Window

Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. Read More

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$10.26
Change (%) Stock is Down 0.12 (1.16%)
Volume5,669
Data as of October 17, 2017 4:00 p.m. ET
Refresh quote

IR Contact

Gregory Gin
Email: ir@edgetherapeutics.com

Upcoming Events

There are currently no events scheduled.

Presentation

DateTitle
October 4, 2017
Download Documentation Investor Presentation – October 2017

Lastest News

October 6, 2017 - Edge Therapeutics to Present at the Neurocritical Care Society 15th Annual Meeting
Read More
September 20, 2017 - Edge Therapeutics to Present at Upcoming Investor Conferences
Read More
September 19, 2017 - Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors
Read More

More >>

Data provided by Nasdaq. Minimum 15 minutes delayed.